---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-022489"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T04:12:06.577184+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics acquires Exacis Biotherapeutics' IP assets in stock-and-contingent deal

## Summary
- Eterna issued 69,343 shares to Exacis at closing; shares subject to 12-month lockup.
- Contingent milestone: if market cap hits $100M, additional $2M in shares; at $200M, another $2M in shares.
- Eterna to pay Exacis 20% of sublicensing revenue received within 5 years, capped at $45M.
- CEO Matthew Angel is co-founder of Factor Bioscience (Exacis parent); director Gregory Fiore is CEO of Exacis; deal approved by audit committee and disinterested directors.
- Eterna assumes only post-closing liabilities under the purchased license; Exacis retains other liabilities.

## SEC filing metadata
- accession: 0001140361-23-022489
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123022489/0001140361-23-022489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123022489/brhc20052311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-022489
- JSON: https://secwatch.observer/filing/0001140361-23-022489.json
- Plain text: https://secwatch.observer/filing/0001140361-23-022489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.